Over 300 million people worldwide live with a rare disease, yet roughly 95% of these conditions lack an FDA-approved treatment. Traditional clinical trials face significant challenges in this segment. Barriers include small patient populations with correspondingly limited statistical power. Yet emerging biosimulation and virtual trial methods offer a promising path forward., says Oxana Iliach, vice-chair…